Only months after introducing its Functional Anatomic Mapping technology at the Society of Nuclear Medicine meeting (SCAN 6/23/99), GE Medical Systems has won clearance for the technique from the Food and Drug Administration. The technology
Only months after introducing its Functional Anatomic Mapping technology at the Society of Nuclear Medicine meeting (SCAN 6/23/99), GE Medical Systems has won clearance for the technique from the Food and Drug Administration. The technology combines x-ray tomographic capability with a gamma camera, enhancing anatomic detail with functional capabilities. Millennium VG gamma cameras with the technology have been installed at such clinical sites as Vanderbilt University in Nashville, TN, and Rambam Medical Center in Israel. The Milwaukee-based company expects Functional Anatomic Mapping to be available to clinicians next year, according to Beth Klein, general manager of global nuclear medicine/PET for GEMS.
In other news, GE and OEC Medical Systems announced last month that the antitrust waiting period for the two firms planned merger, in connection with the governments review of the deal, has expired. GE and OEC signed a definitive merger agreement in August in a transaction estimated at $480 million (SCAN 8/18/99). Milwaukee-based GE attributed its interest in OEC to OECs strong position in the fluoroscopy and surgical x-ray markets. The deal will be put before OEC shareholders for approval at a meeting Nov. 29. If shareholders vote to approve the merger, it will close immediately following the meeting and OEC shareholders will receive approximately $36 per share, payable in GE common stock.
Also last month, GE introduced MINItrace, a cyclotron designed to produce radiopharmaceuticals for individual PET sites (SCAN 5/26/99). With MINItrace, GE hopes to reduce the cost of producing cancer-detecting tracers and facilitate their use in neighborhood hospitals and clinics.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.